Phase I/II Trial Evaluating Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung

Investigating Radiation Dosage for Lung Cancer Treatment

Recruiting
18 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to test whether 5 fraction stereotactic ablative body radiation (SABR) is safe and improves local control for early state squamous cell carcinoma of the lung.

Detailed description of study

The purpose of this study is to evaluate the amount of radiation used in stereotactic ablative ratiotherapy (SABR). This study asks if patients with non-small cell lung cancer of the lung squamous cell subtype can safely receive more radiation. If a higher radiation dose is found to be safe, the study then asks if that higher dose can control the cancer better than the current standard dose.
Participants will not be paid for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: lung cancer
  • Age: 18 years - 100 years
  • Gender: All

Inclusion Criteria
Pathological diagnosis of squamous cell carcinoma of the lung
Exclusion Criteria
Previous radiation therapy to the lung per investigator discretion

Updated on 19 Feb 2024. Study ID: 1706985235 (IUSCC-0624)

This study investigates whether a specific type of radiation therapy, called stereotactic ablative body radiation (SABR), is safe and effective for treating early-stage squamous cell carcinoma of the lung. Squamous cell carcinoma is a kind of lung cancer that starts in the flat cells lining the lungs. The study aims to find out if patients can safely receive higher doses of radiation than what is currently standard.

Participants in this study will receive SABR, which involves targeted radiation treatment. The study will compare the effects of a higher dose of radiation to the standard dose to see if it better controls the cancer. The safety of these doses will also be evaluated throughout the study.

  • Who can participate: Individuals with a confirmed diagnosis of squamous cell carcinoma of the lung can participate. Those who have previously received radiation therapy to the lung are not eligible.
  • Study details: Participants will receive a type of radiation treatment called SABR. The study will involve comparing different doses of radiation to determine their safety and effectiveness.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here